“There is no \u00a0gene\u00a0 for the \u00a0human spirit\u00a0,” cautions the protagonist of *Gattaca*, a film envisioning a future where one’s DNA dictates their societal value. In this dystopian world, genetic selection at birth not only determines \u00a0professions\u00a0 but also predestines life paths. What was once mere science fiction has begun to inch closer to reality\u2014particularly in Silicon Valley, the heart of technological innovation. Here, a burgeoning market aims to optimize future generations even before birth.<\/p>\n
<\/p>\n
A recent report by The Wall Street Journal<\/a> reveals how startups such as Nucleus Genomics, Herasight, and Orchid Health have ventured into the realm of \u00a0embryo screening\u00a0 that transcends traditional in vitro fertilization (IVF). Previously, the focus was primarily on eliminating severe chromosomal anomalies like cystic fibrosis or Down syndrome. Now, the stakes are higher, with the inclusion of predictions regarding \u00a0IQ\u00a0 and the likelihood of major diseases such as \u00a0Alzheimer’s\u00a0, \u00a0cancer\u00a0, and \u00a0diabetes\u00a0.<\/p>\n <\/p>\n The costs for this genetic screening can be staggering. Orchid charges around \u00a0$2,500\u00a0 per embryo analyzed, while a complete IVF cycle\u2014including screening\u2014can total upwards of \u00a0$20,000\u00a0, according to The Washington Post<\/a>. Other services range from \u00a0$6,000\u00a0 at Nucleus to \u00a0$50,000\u00a0 at Herasight. The clientele predominantly consists of Silicon Valley\u2019s technological elite\u2014so much so that matrimonial agents have emerged to match couples with high IQs for the purpose of \u00a0\u201ccreating smart children.\u201d\u00a0 Elon Musk has even advocated that individuals with exceptional intellectual capabilities should reproduce at higher rates.<\/p>\n <\/p>\n Beneath the frenzy surrounding genetic screening in Silicon Valley lies a spectrum of motivations. While some future parents primarily focus on the \u00a0medical\u00a0 aspect\u2014minimizing the risk of genetic diseases\u2014others are driven by broader, societal ambitions. For instance, Simone and Malcolm Collins, mentioned in the *Wall Street Journal*, opted for an embryo with a low cancer probability, while also benefiting from a projected IQ in the \u00a099th percentile\u00a0 through Herasight.<\/p>\n <\/p>\n Conversely, others are up front about their cognitive aspirations. Mathematician TSVI Benson-Tilsen, co-founder of the Berkeley Genomics Project, told the *WSJ* that his goal is to “create more geniuses” capable of managing global challenges like runaway artificial intelligence. These objectives often align with a rising \u00a0pronatalist\u00a0 ideology in the U.S., gaining traction among figures like Elon Musk and Vice President JD Vance.<\/p>\n <\/p>\n The journey toward an “optimized baby” begins similarly to conventional IVF: ovarian stimulation, egg retrieval, and laboratory fertilization. The process can be expensive\u2014reported costs for just the IVF step can reach \u00a0$20,000\u00a0, excluding additional genetic analysis. After about five days of development, between five and ten cells are extracted from each embryo at the blastocyst stage for genetic sequencing. However, amplifying such a small amount of DNA can lead to errors.<\/p>\n <\/p>\n Companies leverage complex algorithms to assess risks and predict traits based on genetic data. The results resemble financial spreadsheets more than medical reports: asking questions like, “How many IQ points compensate for a 1% increased risk of ADHD?” or “What risk of Alzheimer’s is acceptable for a reduced chance of bipolar disorder?” This meticulous reproductive engineering culminates in the selection of an embryo that ostensibly maximizes health and intellectual prospects.<\/p>\n <\/p>\n Despite the promising rhetoric surrounding these startups, the scientific foundations underpinning their claims are shaky. The *Wall Street Journal* has reported warnings from geneticist Shai Carmi, who notes that existing polygenic prediction models account for merely \u00a05% to 10%\u00a0 of the variation in IQ among individuals. This implies that choosing an embryo based on these models might only yield an incremental IQ gain of three or four points compared to a randomly selected embryo.<\/p>\n <\/p>\n The amplification of a few cells introduces another layer of complication, with Stanford Geneticist Svetlana Yatsenko likening the process to “playing Russian roulette.” A mutation might appear as present or absent, solely due to amplification errors\u2014not reflective of the embryo’s genetic reality.<\/p>\n <\/p>\n Furthermore, there is a demographic skew in these genetic databases, primarily derived from European populations, leading to less accurate predictions for individuals with diverse ancestries. While companies like Orchid attempt to correct for this bias, the challenge remains a noteworthy concern.<\/p>\n <\/p>\n Choosing embryos based on specific traits presents complexities that can result in unintended consequences. Researchers like Sasha Gustav from Harvard have highlighted that picking for high IQ may simultaneously increase genetic susceptibility to conditions such as autism spectrum disorders. Genes often do not operate in isolation, and optimizing one quality could inadvertently compromise another.<\/p>\n <\/p>\n Additionally, this practice raises questions about a potential new form of \u00a0eugenics\u00a0, whether voluntary or not. Bioethicist Lior Pachter has argued that translating the human genome into a set of numerical scores inherently promotes the notion that certain genes are superior, which could deepen social divides based on genetic advantages. Proponents, including Benson-Tilsen and the Collins couple, argue that their focus is on ensuring the best opportunities for their children\u2014not fostering discrimination.<\/p>\n <\/p>\n The conversation around genetic screening is no longer confined to academic or medical discourse; it has seeped into broader cultural conversations. The \u00a0pronatalist\u00a0 rhetoric in the U.S., championed by influential figures, intermingles with Silicon Valley’s investment in reproductive technologies. Industry leaders like Peter Thiel and Brian Armstrong have recognized this sector as a lucrative and impactful frontier for humanity’s future, pushing the conversation from fringe to mainstream.<\/p>\n <\/p>\n As Silicon Valley ponders the potential to create children with unparalleled health and intelligence, the discussion evolves from mere \u00a0preventive medicine\u00a0 to a broader dialogue about societal implications. Whether seen as a ground-breaking medical advancement or a dangerous step toward a genetically divided society, the reality remains: as we contemplate optimizing the next generation, the question lingers\u2014who ultimately decides what it means to be “better”?<\/p>\n <\/p>\n Image credit: Pexels<\/a> and Pixabay<\/a><\/p>\n Xataka | Sydney Sweeney stars in a new commercial for jeans, igniting a conversation about the evolving relationship between genetics and consumer culture.<\/p>\nPrevention or Social Engineering?<\/h2>\n
The Genetic Selection Process<\/h2>\n
Science Under Scrutiny<\/h2>\n
The Ethical Quandaries<\/h2>\n
Pronatalism and Eugenics Intertwined<\/h2>\n
The Spreadsheet Future<\/h2>\n